Measles-Containing Vaccine Use for Children Aged 12 to 47 Months, 2015 to 2025
-
By
-
Meaghan S. Fagalde
-
Libby C. Page
-
Ellyn P. Marder
-
M. Mia Shim
-
Sharon Bogan
-
Disha Patel
-
Meagan K. Kay
-
Eric J. Chow
-
July 10, 2026
-
Clinical Scorecard: Utilization of Measles-Containing Vaccines in Children Aged 12 to 47 Months from 2015 to 2025
At a Glance
| Category | Detail |
|---|
| Condition | Measles-containing vaccines (MCV) |
| Key Mechanisms | Preventing infection and community transmission of measles and varicella. |
| Target Population | Children aged 12 to 47 months in King County, Washington. |
| Care Setting | Public health surveillance and vaccination clinics. |
Key Highlights
- 64% of children received coadministered MMR + VAR as their first dose.
- 15% of children received MMRV as their first MCV and VCV dose.
- Significantly more MMRV-receiving children were from minoritized racial and ethnic groups.
- 95% of children received both MCV and VCV before age 4 years.
- Racial and ethnic disparities in vaccination coverage have declined since the VFC program implementation.
Guideline-Based Recommendations
Diagnosis
Management
- ACIP recommends coadministered MMR and VAR (MMR + VAR) as the preferred first dose for children younger than 4 years.
Monitoring & Follow-up
Risks
- Increased risk of febrile seizures associated with MMRV.
Patient & Prescribing Data
Children aged 12 to 47 months in King County, Washington.
Combination vaccines like MMRV improve coverage by reducing the number of injections and clinic visits.
Clinical Best Practices
- Ensure access to recommended vaccines for VFC-eligible children.
- Monitor vaccination patterns to identify populations at risk of not receiving recommended vaccines.
Related Resources & Content
